OLIG2 expression level could be used as an independent prognostic factor for patients with cerebellar Glioblastoma (cGBM)
Autor(a) principal: | |
---|---|
Data de Publicação: | 2023 |
Outros Autores: | , , , , , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Clinics |
Texto Completo: | https://www.revistas.usp.br/clinics/article/view/213766 |
Resumo: | Objectives: The incidence of cerebellar Glioblastoma Multiforme (cGBM) is rare. Database like TCGA have not distinguish cGBM from GBM, our knowledge on cGBM gene expression characteristics is limited. The expression status of Oligodendrocyte Lineage Transcription factor 2 (OLIG2) and its clinical significance in cGBM is still unclear. Methods: The clinical data and tissue specimens of 73 cGBM patients were retrospectively studied. The association between OLIG2 expression level and the demographic characteristics of cGBM patients was identified by the Chi-Square test. The survival curves were drawn by Kaplan-Meier analysis. The independent prognostic factors was calculated according to Cox regression analysis. Results: The OLIG2 high expression was observed in about 57.5% (42/73) of the cGBM patients. Patients with high OLIG2 expression levels had a higher alive ratio at the end of follow-up (alive ratio: 70.6% vs. 29.4%, p = 0.04). The median survival time was 21 months and 13 months for high and low expression of OLIG2 (p < 0 .05). Univariate analysis and Multivariate analysis indicated that EOR (HR = 3.89, 95% CI 1.23‒12.26, p = 0.02), low OLIG2 expression (HR = 5.26, 95% CI 1.13‒24.59, p = 0.04), and without adjuvant therapy (HR = 4.95, 95% CI 1.22‒20.00, p = 0.03) were independent risk factors for the OS of cGBM patients. Conclusion: High expression level of OLIG2 could be used as an independent favorable prognosis indicator in cGBM patients and be recognized as a characteristic biomarker of cGBM. |
id |
USP-19_5951512ceac42b626b52fc0e996b2adc |
---|---|
oai_identifier_str |
oai:revistas.usp.br:article/213766 |
network_acronym_str |
USP-19 |
network_name_str |
Clinics |
repository_id_str |
|
spelling |
OLIG2 expression level could be used as an independent prognostic factor for patients with cerebellar Glioblastoma (cGBM)Cerebellar Glioblastoma MultiformeOLIG2BiomarkersMolecular pathologyObjectives: The incidence of cerebellar Glioblastoma Multiforme (cGBM) is rare. Database like TCGA have not distinguish cGBM from GBM, our knowledge on cGBM gene expression characteristics is limited. The expression status of Oligodendrocyte Lineage Transcription factor 2 (OLIG2) and its clinical significance in cGBM is still unclear. Methods: The clinical data and tissue specimens of 73 cGBM patients were retrospectively studied. The association between OLIG2 expression level and the demographic characteristics of cGBM patients was identified by the Chi-Square test. The survival curves were drawn by Kaplan-Meier analysis. The independent prognostic factors was calculated according to Cox regression analysis. Results: The OLIG2 high expression was observed in about 57.5% (42/73) of the cGBM patients. Patients with high OLIG2 expression levels had a higher alive ratio at the end of follow-up (alive ratio: 70.6% vs. 29.4%, p = 0.04). The median survival time was 21 months and 13 months for high and low expression of OLIG2 (p < 0 .05). Univariate analysis and Multivariate analysis indicated that EOR (HR = 3.89, 95% CI 1.23‒12.26, p = 0.02), low OLIG2 expression (HR = 5.26, 95% CI 1.13‒24.59, p = 0.04), and without adjuvant therapy (HR = 4.95, 95% CI 1.22‒20.00, p = 0.03) were independent risk factors for the OS of cGBM patients. Conclusion: High expression level of OLIG2 could be used as an independent favorable prognosis indicator in cGBM patients and be recognized as a characteristic biomarker of cGBM.Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo2023-03-30info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfhttps://www.revistas.usp.br/clinics/article/view/21376610.1016/j.clinsp.2022.100120Clinics; Vol. 78 (2023); 100120Clinics; v. 78 (2023); 100120Clinics; Vol. 78 (2023); 1001201980-53221807-5932reponame:Clinicsinstname:Universidade de São Paulo (USP)instacron:USPenghttps://www.revistas.usp.br/clinics/article/view/213766/195925Copyright (c) 2023 Clinicsinfo:eu-repo/semantics/openAccessZhou, JiaShi, Ling-FeiWang, ZhengLi, MinZhang, Jin-SengMao, YingHua, Wei2023-07-06T13:05:38Zoai:revistas.usp.br:article/213766Revistahttps://www.revistas.usp.br/clinicsPUBhttps://www.revistas.usp.br/clinics/oai||clinics@hc.fm.usp.br1980-53221807-5932opendoar:2023-07-06T13:05:38Clinics - Universidade de São Paulo (USP)false |
dc.title.none.fl_str_mv |
OLIG2 expression level could be used as an independent prognostic factor for patients with cerebellar Glioblastoma (cGBM) |
title |
OLIG2 expression level could be used as an independent prognostic factor for patients with cerebellar Glioblastoma (cGBM) |
spellingShingle |
OLIG2 expression level could be used as an independent prognostic factor for patients with cerebellar Glioblastoma (cGBM) Zhou, Jia Cerebellar Glioblastoma Multiforme OLIG2 Biomarkers Molecular pathology |
title_short |
OLIG2 expression level could be used as an independent prognostic factor for patients with cerebellar Glioblastoma (cGBM) |
title_full |
OLIG2 expression level could be used as an independent prognostic factor for patients with cerebellar Glioblastoma (cGBM) |
title_fullStr |
OLIG2 expression level could be used as an independent prognostic factor for patients with cerebellar Glioblastoma (cGBM) |
title_full_unstemmed |
OLIG2 expression level could be used as an independent prognostic factor for patients with cerebellar Glioblastoma (cGBM) |
title_sort |
OLIG2 expression level could be used as an independent prognostic factor for patients with cerebellar Glioblastoma (cGBM) |
author |
Zhou, Jia |
author_facet |
Zhou, Jia Shi, Ling-Fei Wang, Zheng Li, Min Zhang, Jin-Seng Mao, Ying Hua, Wei |
author_role |
author |
author2 |
Shi, Ling-Fei Wang, Zheng Li, Min Zhang, Jin-Seng Mao, Ying Hua, Wei |
author2_role |
author author author author author author |
dc.contributor.author.fl_str_mv |
Zhou, Jia Shi, Ling-Fei Wang, Zheng Li, Min Zhang, Jin-Seng Mao, Ying Hua, Wei |
dc.subject.por.fl_str_mv |
Cerebellar Glioblastoma Multiforme OLIG2 Biomarkers Molecular pathology |
topic |
Cerebellar Glioblastoma Multiforme OLIG2 Biomarkers Molecular pathology |
description |
Objectives: The incidence of cerebellar Glioblastoma Multiforme (cGBM) is rare. Database like TCGA have not distinguish cGBM from GBM, our knowledge on cGBM gene expression characteristics is limited. The expression status of Oligodendrocyte Lineage Transcription factor 2 (OLIG2) and its clinical significance in cGBM is still unclear. Methods: The clinical data and tissue specimens of 73 cGBM patients were retrospectively studied. The association between OLIG2 expression level and the demographic characteristics of cGBM patients was identified by the Chi-Square test. The survival curves were drawn by Kaplan-Meier analysis. The independent prognostic factors was calculated according to Cox regression analysis. Results: The OLIG2 high expression was observed in about 57.5% (42/73) of the cGBM patients. Patients with high OLIG2 expression levels had a higher alive ratio at the end of follow-up (alive ratio: 70.6% vs. 29.4%, p = 0.04). The median survival time was 21 months and 13 months for high and low expression of OLIG2 (p < 0 .05). Univariate analysis and Multivariate analysis indicated that EOR (HR = 3.89, 95% CI 1.23‒12.26, p = 0.02), low OLIG2 expression (HR = 5.26, 95% CI 1.13‒24.59, p = 0.04), and without adjuvant therapy (HR = 4.95, 95% CI 1.22‒20.00, p = 0.03) were independent risk factors for the OS of cGBM patients. Conclusion: High expression level of OLIG2 could be used as an independent favorable prognosis indicator in cGBM patients and be recognized as a characteristic biomarker of cGBM. |
publishDate |
2023 |
dc.date.none.fl_str_mv |
2023-03-30 |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
https://www.revistas.usp.br/clinics/article/view/213766 10.1016/j.clinsp.2022.100120 |
url |
https://www.revistas.usp.br/clinics/article/view/213766 |
identifier_str_mv |
10.1016/j.clinsp.2022.100120 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
https://www.revistas.usp.br/clinics/article/view/213766/195925 |
dc.rights.driver.fl_str_mv |
Copyright (c) 2023 Clinics info:eu-repo/semantics/openAccess |
rights_invalid_str_mv |
Copyright (c) 2023 Clinics |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf |
dc.publisher.none.fl_str_mv |
Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo |
publisher.none.fl_str_mv |
Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo |
dc.source.none.fl_str_mv |
Clinics; Vol. 78 (2023); 100120 Clinics; v. 78 (2023); 100120 Clinics; Vol. 78 (2023); 100120 1980-5322 1807-5932 reponame:Clinics instname:Universidade de São Paulo (USP) instacron:USP |
instname_str |
Universidade de São Paulo (USP) |
instacron_str |
USP |
institution |
USP |
reponame_str |
Clinics |
collection |
Clinics |
repository.name.fl_str_mv |
Clinics - Universidade de São Paulo (USP) |
repository.mail.fl_str_mv |
||clinics@hc.fm.usp.br |
_version_ |
1800222767349497856 |